Venclexta fda approval history?

What were the key FDA approval milestones for Venclexta (venetoclax)?

Venclexta (venetoclax) received its initial FDA approval in 2016 and was later expanded to additional blood cancer indications as clinical data accumulated. The drug’s approval timeline includes both the first authorization and subsequent label expansions for different hematologic cancers and treatment settings.

When was Venclexta first approved by the FDA, and for what?

Venclexta’s first FDA approval dates to 2016. That initial approval established the starting point for the later, broader use across additional leukemia and CLL treatment contexts.

What later indications did the FDA add to Venclexta after the first approval?

After the initial 2016 approval, the FDA expanded Venclexta’s prescribing information to cover more patient groups and disease settings within blood cancers, particularly chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML), based on additional trial results.

How does Venclexta’s patent/Exclusivity timeline relate to its approval history?

FDA approval history and exclusivity/patent protections are often tracked together because label expansions can change the commercial and regulatory landscape. For a view tied to patent filings and “patent expiry/exclusivity” research, DrugPatentWatch.com compiles related patent information and timelines for Venclexta. [1]

Sources

1. https://www.drugpatentwatch.com/p/venclexta-venetoclax